Get the Stockscreener App
21.04
4.57%
0.92
Neurogene Inc stock is traded at $21.04, with a volume of 412.85K.
It is up +4.57% in the last 24 hours and down -33.84% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$20.12
Open:
$20.06
24h Volume:
412.85K
Relative Volume:
1.79
Market Cap:
$325.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.24%
1M Performance:
-33.84%
6M Performance:
-2.91%
1Y Performance:
-4.45%
1-Day Range:
$19.88
$23.00
1-Week Range:
$19.23
$23.00
52-Week Range:
$6.875
$37.27
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
21.04 | 311.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Will Neurogene Inc. (UU8) stock rise with strong economyEarnings Growth Summary & Weekly Market Pulse Updates - Newser
Will Neurogene Inc. (UU8) stock keep high P E multiplesCPI Data & Low Volatility Stock Recommendations - Newser
How Neurogene Inc. stock reacts to job market data2025 Dividend Review & Free High Accuracy Swing Entry Alerts - Newser
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Swing Trade: Can Neurogene Inc stock deliver surprise earnings beatJuly 2025 Retail & Weekly High Momentum Picks - BỘ NỘI VỤ
Will Neurogene Inc. (UU8) stock outperform value peers2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Will Neurogene Inc. (UU8) stock profit from automation waveJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50 - Defense World
Is Neurogene Inc. (UU8) stock safe for risk averse investorsJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Is Neurogene Inc. (UU8) stock inflation resilientQuarterly Performance Summary & Risk Managed Trade Strategies - Newser
How institutional buying supports Neurogene Inc. stock2025 Market Sentiment & Verified Technical Trade Signals - Newser
Will Neurogene Inc. (UU8) stock outperform benchmarksJuly 2025 EndofMonth & Community Consensus Stock Picks - Newser
Neurogene (NGNE) Stock Analysis Report | Financials & Insights - Benzinga
How Neurogene Inc. (UU8) stock correlates with oil markets2025 Geopolitical Influence & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Is Neurogene Inc a good long term investmentPortfolio Diversification Tips & Small Budget Wealth Tips - earlytimes.in
Wall Street analysts’ outlook for Neurogene Inc (NGNE) - Setenews
Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth - Yahoo Finance
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE) - Seeking Alpha
EBIT per share of Neurogene Inc. – FWB:UU8 - TradingView
Neurogene (NGNE) Price Target Increased by 11.85% to 60.18 - MSN
Neurogene Inc Stock Analysis and ForecastTake Profit Strategies & Start Your Free Trading Journey Today - earlytimes.in
How Neurogene Inc. (UU8) stock reacts to Fed tighteningWeekly Market Outlook & Weekly Chart Analysis and Trade Guides - newser.com
Statistical indicators supporting Neurogene Inc.’s strengthJuly 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Will Neurogene Inc. (UU8) stock beat international competitionMarket Movers & Long-Term Growth Plans - newser.com
Can Neurogene Inc. (UU8) stock deliver strong annual returnsGlobal Markets & Accurate Trade Setup Notifications - newser.com
Is Neurogene Inc. (UU8) stock cheap by valuation metricsMarket Risk Analysis & Short-Term Trading Alerts - newser.com
Can Neurogene Inc. stock withstand economic slowdownMarket Activity Report & Free Fast Gain Swing Trade Alerts - newser.com
Using AI based signals to follow Neurogene Inc.New Guidance & Intraday High Probability Alerts - newser.com
Is Neurogene Inc. (UU8) stock expanding market penetrationQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Signal strength of Neurogene Inc. stock in tech scannersJuly 2025 Market Mood & Weekly High Potential Stock Alerts - newser.com
Is Neurogene Inc. stock a buy on dipsWeekly Investment Report & Safe Entry Point Identification - newser.com
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):